Theriva Biologics Faces Liquidity Crisis: Urgent Capital Needed to Sustain Operations and Clinical Programs
Theriva Biologics Reports $18.3M In Cash For Q1 2024, Which Is Expected To Provide Runway Into The First Quarter Of 2025
Theriva Biologics Reports $18.3M In Cash For Q1 2024, Which Is Expected To Provide Runway Into The First Quarter Of 2025
Theriva Biologics | 10-Q: Quarterly report
Theriva Biologics Q1 2024 GAAP EPS $(0.30) Misses $(0.27) Estimate
Theriva Biologics Q1 2024 GAAP EPS $(0.30) Misses $(0.27) Estimate
Theriva Biologics 1Q Loss/Shr 30c >TOVX
Theriva Biologics 1Q Loss/Shr 30c >TOVX
Press Release: Theriva(TM) Biologics Reports First Quarter 2024 Operational Highlights and Financial Results
Theriva(TM) Biologics Reports First Quarter 2024 Operational Highlights and Financial Results - Reported topline data from the investigator sponsored Phase 1 trial of intravitreal VCN-01 in pediatric
Theriva Biologics Files Mixed-Securities Shelf
Theriva Biologics Files Mixed-Securities Shelf
Theriva Biologics To Discuss The Trial Design For VIRAGE - A Phase 2b Clinical Study Of Systemically Administered VCN-01 In Combination With Chemotherapy In Pancreatic Ductal Adenocarcinoma At The 2024 ASCO Annual Meeting
Theriva Biologics (NYSE:TOVX), a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas of high unmet need, today announced that, based on th
Theriva Biologics Disclosed Positive Topline Data From Investigator Sponsored Phase 1 Trial Of Intravitreal VCN-01 In Pediatric Patients With Refractory Retinoblastoma
Theriva Biologics Disclosed Positive Topline Data From Investigator Sponsored Phase 1 Trial Of Intravitreal VCN-01 In Pediatric Patients With Refractory Retinoblastoma
Theriva Biologics' VCN-01 Shows Promise in Pediatric Cancer Trial
Theriva Biologics Reports Breakthrough in Pancreatic Cancer Therapy
Theriva Biologics To Present Preclinical Data For Potential Synergy Of VCN-01 And First-Line Pancreatic Cancer Chemotherapy Regimens At American Society For Cell And Gene Therapy 27th Annual Meeting
– Lead product candidate, VCN-01 in combination with liposomal irinotecan demonstrated enhanced anti-tumor effects in a human pancreatic mouse xenograft–– The observed synergy emphasizes VCN-01's pote
Theriva Biologics to Present Preclinical Data Supporting the Potential Synergy of VCN-01 and First-Line Pancreatic Cancer Chemotherapy Regimens at the American Society for Cell and Gene Therapy 27th Annual Meeting
Theriva Biologics (NYSE American: TOVX) today announced the presentation of preclinical data demonstrating enhanced anti-tumor effects in human pancreatic cancer xenograft-bearing mice treated with lead product candidate VCN-01 and liposomal irinotecan.
Theriva Biologics Upcoming Investor Presentations Insight
Buy Recommendation for Theriva Biologics Backed by Promising Oncolytic Adenovirus Platform and Clinical Trial Advancements
Q4 2023 Theriva Biologics Inc Earnings Call
Earnings Call Summary | Theriva Biologics(TOVX.US) Q4 2023 Earnings Conference
The following is a summary of the Theriva Biologics, Inc. (TOVX) Q4 2023 Earnings Call Transcript:Financial Performance:Theriva Biologics reported a decrease in general and administrative expenses fro
Theriva Biologics GAAP EPS of -$1.14 Beats by $0.23
Theriva Biologics FY EPS $(1.14) Beats $(1.28) Estimate; As Of December 31, 2023, Theriva Biologics Reports $23.2M In Cash, Which Is Expected To Provide Runway Into The First Quarter Of 2025
Theriva Biologics (AMEX:TOVX) reported quarterly losses of $(1.14) per share which beat the analyst consensus estimate of $(1.28) by 10.94 percent. This is a 12.98 percent increase over losses of $(1.
Earnings Scheduled For March 25, 2024
Companies Reporting Before The Bell • Bitcoin Depot (NASDAQ:BTM) is expected to report quarterly loss at $0.08 per share on revenue of $161.50 million. • Syra Health (NASDAQ:SYRA) is likely to report
No Data